A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

Recruiting in Palo Alto (17 mi)

+32 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Eli Lilly and Company

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a new medication called LY3437943 to help people who are obese or overweight lose weight. The study will last over a year and involve multiple visits. The medication works by affecting the body's metabolism and appetite to promote weight loss.

Research Team

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

Inclusion Criteria

Participants must have a Body Mass Index (BMI) ) ≥30 and ≤50 kilograms per square meter (kg/m²), or ≥27 kg/m² and <30 kg/m², with at least one of the following comorbidities: hypertension, dyslipidemia, cardiovascular disease

Participants must be willing to learn how to self-inject study drug or receive an injection from a trained individual if visually impaired or with physical limitations, and follow study procedures for the duration of the study, including, but not limited to, follow lifestyle advice (for example, dietary changes and physical activity plan), maintain a study drug administration log, and complete required questionnaires

Treatment Details

Interventions

LY3437943 (Other)
Placebo (Other)

Participant Groups

7Treatment groups

Experimental Treatment

Placebo Group

Group I: 8 mg LY3437943 (4 mg)Experimental Treatment1 Intervention

Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.

Group II: 8 mg LY3437943 (2 mg)Experimental Treatment1 Intervention

Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.

Group III: 4 mg LY3437943 (2 mg)Experimental Treatment1 Intervention

Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.

Group IV: 4 mg LY3437943Experimental Treatment1 Intervention

Participants received 4 mg LY3437943 administered as SC injection QW.

Group V: 12 mg LY3437943 (2 mg)Experimental Treatment1 Intervention

Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.

Group VI: 1 milligram (mg) LY3437943Experimental Treatment1 Intervention

Participants received 1 mg LY3437943 administered as SC injection QW.

Group VII: PlaceboPlacebo Group1 Intervention

Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).